Cytokinetics (CYTK) FY2015 results: revenue $29 million, down 38.9% on the year
Cytokinetics Inc. (CYTK) reported revenue of $29 million for fiscal 2015, the year ended 31 December 2015, down 38.9% on the year before. Net income was -$38 million, and diluted earnings per share $-0.97. The figures are the company's own, from the 10-K it filed with the SEC on 3 March 2016.
Revenue
$29 million
-38.9% on the year
FY2009FY2015
Operating margin
-130.5%
-31.4% a year earlier
FY2009FY2015
Net income
-$38 million
FY2009FY2015
Diluted EPS
-$0.97
FY2009FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
28.7
46.9
30.6
-38.9%
Research and development
46.4
44.4
49.5
+4.4%
Operating income
-37.4
-14.8
-33.9
Operating margin
-130.5%
-31.4%
-110.6%
Interest expense
0.3
0.0
0.0
Pre-tax income
-37.5
-14.6
-33.7
Income tax
0.0
0.0
0.0
Net income
-37.5
-14.6
-33.7
Net margin
-130.9%
-31.2%
-110.0%
Diluted EPS
-$0.97
-$0.41
-$1.24
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
4.9
-44.8
-7.7
Capital expenditure
0.6
1.1
0.5
-49.1%
Free cash flow
4.3
-45.9
-8.3
Free cash flow margin
15.1%
-97.9%
-27.0%
Cash from investing
n/a
n/a
-1.5
Cash from financing
n/a
n/a
14.5
Depreciation and amortisation
0.6
0.5
0.4
+20.2%
Share-based compensation
4.6
3.3
3.6
+37.1%
Diluted shares, weighted
39m
36m
n/a
+8.7%
Shares outstanding at period end
40m
39m
31m
+2.4%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
68.6
92.1
54.4
-25.5%
Debt
14.6
0.0
0.0
Other liabilities
32.0
40.9
28.7
-21.7%
Total liabilities and equity
115
133
83.2
-13.3%
Fixed assets
1.8
1.6
1.2
+7.0%
Investments
46.5
63.0
60.1
-26.1%
Cash and equivalents
65.1
20.2
20.2
+221.9%
Other assets
1.9
48.1
1.7
-96.1%
Total assets
115
133
83.2
-13.3%
10-K for the year ended 31 December 2015, filed 3 March 2016: the filing.